Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Quotes and News

Ligand Pharmaceuticals Incorporated (LGND) 28.00 1.32

Price Open:	26.97	Day's Range:	14.78000 - 29.87900
Price Close:	26.69	52wk Range:	10.50 - 29.87900
Price Day Change:	1.32	Volume:	134,125
Price % Change:	4.95	Market Cap:	565.5M
Bid:	25.00000	PE Ratio:	0
Ask:	28.00000	EPS Diluted:	-0.008

Trade LGND NOW!

The Latest On LGND

Ligand Partner Rib-X Initiates Phase 3 Trial of Captisol-enabled™ Delafloxacin IV 5/14/13 8:33am

Ligand Announces $5M Buyback, Q1 Earnings 5/8/13 4:14pm

Stocks Hitting 52-Week Highs 4/22/13 10:34am

UPDATE: Cantor Fitzgerald Raises PT on Ligand Pharmaceuticals on Announced Spectrum Partnership 3/18/13 8:30am

Ligand, Spectrum Pharmaceuticals in Global License Agreement 3/14/13 7:02am

Ligand Pharma Wins Equity Milestone Payment from Retrophin 1/9/13 10:01am

UPDATE: Cantor Fitzgerald Downgrades Ligand Pharmaceuticals to Hold, Lowers PT 1/4/13 9:38am

FDA Accepts NDA for Pfizer, Ligand's Bazedoxifene/Conjugated Estrogens 12/13/12 6:05pm

Ligand Pharma Begins Pivotal Trial of Captisol-Enabled Propylene Glycol-Free Melphalan for Multiple Myeloma Patients 12/10/12 5:09pm

UPDATE: Cantor Fitzgerald Reiterates Buy Rating, Raises PT on Ligand Pharmaceuticals 12/7/12 11:48am

Benzinga's Volume Movers 11/19/12 11:46am

Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication 11/19/12 10:11am

Press Releases

Ligand Partner Rib-X Initiates Phase 3 Trial of Captisol-enabled™ Delafloxacin IV 5/14/13 Business Wire

Ligand Reports First Quarter Financial Results 5/8/13 Business Wire

Ligand Acquires Financial Rights to More Than 15 Fully-Funded Development Programs from Selexis SA 4/30/13 Business Wire

Ligand Presents Preclinical Data on HepDirect™ Liver-Targeting Technology Platform at 2013 International Liver Congress (EASL) Annual Meeting 4/26/13 Business Wire

Ligand to Present at Upcoming Investor Conferences 4/23/13 Business Wire

Ligand to Report First Quarter Results on May 8th 4/22/13 Business Wire

Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled® Melphalan 3/14/13 Business Wire

Ligand Signs Global License Agreement with Spectrum Pharmaceuticals for Captisol-Enabled® Melphalan 3/14/13 Business Wire

Ligand Receives $1.4 Million Milestone Payment from Retrophin, Inc. 2/25/13 Business Wire

Ligand Reports Fourth Quarter and Full Year 2012 Financial Results 2/13/13 Business Wire

Ligand to Report Fourth Quarter Results on February 13th 1/23/13 Business Wire

Ligand Receives Equity Milestone Payment from Retrophin 1/9/13 Business Wire

Get the latest LGND stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Ligand Pharmaceuticals Incorporated stock price.

Partner Headlines

SPPI Acquires Late-Stage Candidate - Analyst Blog 3/18/13

Ligand Pharmaceuticals, Inc. (LGND) CEO John L Higgins buys 2,000 Shares 12/5/12

Glaxo's Promacta Label Expanded - Analyst Blog 11/20/12

Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) 11/14/12

Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q/A) 11/14/12

Ligand Pharmaceuticals Inc. Reports Operating Results (10-K/A) 11/14/12

The Medicines Co. Halts MDCO-2010 - Analyst Blog 10/8/12

Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) 8/8/12

MDCO's Cangrelor Enrollment by 4Q - Analyst Blog 7/3/12

One Drugmaker Soars, 1 Falls 6/21/12

Onyx Up, Celgene Down On Cancer Drug News 6/21/12